Adebrelimab with chemoradiation for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have limited-stage small cell lung cancer (the cancer is only in one lung and nearby lymph nodes).
- You are either new to treatment or have had no more than 2 rounds of chemotherapy.
- You are physically active and able to care for yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a CT scan.
- Your blood counts and organ function (liver, kidneys) are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery, followed by surgery and radiation, is effective for limited-stage small cell lung cancer. The goal is to see if this approach helps control the cancer better than standard treatment alone.
This trial tests whether continuing a drug called adebrelimab (an immunotherapy) after standard treatment helps keep limited-stage small cell lung cancer from coming back. It compares adebrelimab with the usual approach of just watching and following up.
This study tests a new maintenance drug (adebrelimab) after standard chemo and radiation in patients with limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back and improves overall survival, compared to standard care.
This trial is for people with limited-stage small cell lung cancer who have finished chemoradiation and still have small amounts of cancer DNA in their blood (called MRD-positive). The study tests a new treatment strategy after chemoradiation, and it may help reduce the chance of the cancer coming back.
This study tests a new immunotherapy drug (adebrelimab) combined with standard chemotherapy and radiation for people with a large, stage III lung cancer that cannot be surgically removed. The goal is to see if adding this drug helps shrink or control the cancer better than treatment without it.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.